The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.
 
Anita Ahmed Turk
No Relationships to Disclose
 
Dustin A. Deming
Consulting or Advisory Role - Novocure
Research Funding - Merck
 
Sam Joseph Lubner
No Relationships to Disclose
 
Daniel Mulkerin
No Relationships to Disclose
 
Noelle K. LoConte
Consulting or Advisory Role - Celgene
 
Amye Tevaarwerk
Other Relationship - Epic Systems (I)
 
Kari Braun Wisinski
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai; Lilly (Inst); Novartis (Inst)
 
Jens C. Eickhoff
Research Funding - Sanofi Pasteur (Inst)
 
Glenn Liu
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Research Funding - Cellectar (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
Other Relationship - AIQ Solutions